China · Biotechnology startup
China · NeuroDawn Pharmaceutical
NeuroDawn Pharmaceutical develops new drugs that are designed to treat central nervous system diseases.
Funding reportedLast round: Series B
Follow NeuroDawn Pharmaceutical and see its new rounds in your feed. Start following
What company datasets say NeuroDawn Pharmaceutical raised
Funding, as reported
Reported in all370Min the source's currency
Rounds4
Last roundSeries B
Last round dateJan 2024
Investors listed8
Biotechnology in China
Startups like it
Is this your company?
Add your raise, your deck and your story, and put NeuroDawn Pharmaceutical in front of investors. Or tell us what we have wrong.